Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global molecular diagnostics market is poised for significant growth, with its value projected to increase from US$ 23 billion in 2024 to US$ 35 billion by the end of 2031, reflecting a compound annual growth rate (CAGR) of 6%. This steady expansion underscores the increasing importance of molecular diagnostics in healthcare.

Market Introduction and Definition

Molecular diagnostics involves analyzing biological markers at the molecular level to detect specific genetic sequences or mutations associated with various diseases. This field has seen substantial advancements and steady market growth due to the rising prevalence of infectious diseases, genetic disorders, and cancer. The growth prospects of the molecular diagnostics industry depend on economic development, infrastructure projects, urbanization rates, and construction activity. Strategic partnerships and collaborations with research institutions, healthcare providers, and technology firms are essential to access expertise, resources, and novel technologies.

According to the Nature Reviews Microbiology Journal, molecular technologies are nimble, rapid, and versatile, making them an effective solution for infectious disease diagnostics in resource-limited settings with diverse potential etiologies. Healthcare systems utilizing molecular diagnostics can achieve economies of scale, maximize limited expertise, and respond quickly to emerging threats.

Market Growth Drivers

Expanding Role of Companion Diagnostics Across Therapeutic Fields

Companion diagnostics, a subset of molecular diagnostics, plays a crucial role in the increased use of targeted medications in oncology and other therapeutic areas. Next-generation sequencing (NGS), using a multi-analyte approach, provides comprehensive biomarker information, integrating precision medicine into everyday clinical practice.

Regulatory agencies like the FDA support the development and use of companion diagnostics, often requiring their approval for related prescription medications. While initially focused on cancer treatments, companion diagnostics are now expanding to other therapeutic areas, including infectious diseases, cardiovascular conditions, and neurological disorders, broadening the market for related diagnostic tools.

Market Restraints

High Cost of Both Equipment and Reagents

Modern molecular diagnostic tools and supplies can be expensive, posing a challenge for laboratories to invest in advanced technology without exceeding their budgets. The high upfront costs of molecular diagnostic equipment discourage smaller labs or establishments with limited finances. Establishing specialized facilities and infrastructure adds to the financial burden.

Reagents, including enzymes, PCR kits, and DNA probes, are also costly. Regular restocking of these consumables adds to the ongoing operating costs, particularly in resource-limited settings. Additionally, maintenance, calibration, and upgrades of equipment contribute to the total cost of ownership.

Skilful Workforce Training

Operating molecular diagnostic equipment requires specific knowledge and skills in molecular biology, genetics, biochemistry, and related fields. Training personnel to use molecular diagnostic equipment and interpret results necessitates investment in training programs, workshops, and educational resources. High training costs can be prohibitive for smaller healthcare organizations or laboratories with limited finances.

Opportunities

Increasing Government Support and Favorable Regulations

The COVID-19 pandemic has significantly boosted the adoption of real-time PCR (RT-PCR) and other molecular diagnostic technologies. The pressure to expand diagnostics rapidly has led to over 3,000 testing laboratories in India alone performing molecular testing. The prevalence of RT-PCR, viral amplification, and genome sequencing is revolutionizing molecular diagnostics.

Differences in legislative stances between the US and the EU regarding laboratory-developed tests (LDTs) and in-house tests present an opportunity for molecular diagnostic companies to drive innovation. Companies can highlight FDA-compliant testing for the US market and position themselves as collaborators supporting improved internal testing capacities in the EU. This strategic approach allows businesses to maximize market share and product offerings by leveraging different regulatory frameworks.

Key Market Players Include

Becton, Dickinson and Company
Bio-Rad Laboratories In
Merck KgaA
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
F. Hoffman - La Roche Ltd.
Illumina, Inc.
Qiagen N.V.
Hologic Inc.
Siemens Healthineers AG
Seegene, Inc.
DiaSorin S.p.A
Grifols, S.A.
bioMerieux
QuidelOrtho Corporation
RapidBio
Abbott Laboratories
Danaher Corporation

Global Molecular Diagnostics Market is Segmented as Below:

By Product Type:

Instruments
- oPolymerase Chain Reaction (PCR) Systems
- oHybridization (In-Situ Hybridization & Fish) Systems
- oDNA Sequencing and Next-Generation Sequencing Platforms
- oMicroarrays
Reagent
- oAntibodies
- oDNA Template
- oDNA Polymerase
- oOligonucleotide Primers
- oDeoxyribonucleotide Triphosphate (dNTPs)
- oBuffer
Assay Kits
Consumables

By Disease Area:

Infectious Disease
Diabetes
Cardiology
Oncology
Nephrology
Autoimmune Disease
Dermatology
Wound Care
Others

By End Use:

Hospitals & Clinics
Diagnostics Laboratories
Academic and Research Institutes
Biopharmaceutical Companies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Molecular Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Price Analysis, 2019 - 2023

3.1. Global Average Price Analysis, by Product Type, US$ Per Unit, 2019 - 2023
3.2. Prominent Factor Affecting Molecular Diagnostics Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Molecular Diagnostics Market Outlook, 2019 - 2031

4.1. Global Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Instruments
    - 4.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 4.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 4.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 4.1.1.1.4. Microarrays
  - 4.1.1.2. Reagent
    - 4.1.1.2.1. Antibodies
    - 4.1.1.2.2. DNA Template
    - 4.1.1.2.3. DNA Polymerase
    - 4.1.1.2.4. Oligonucleotide Primers
    - 4.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 4.1.1.2.6. Buffer
  - 4.1.1.3. Assay Kits
  - 4.1.1.4. Consumables
4.2. Global Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Infectious Disease
  - 4.2.1.2. Diabetes
  - 4.2.1.3. Cardiology
  - 4.2.1.4. Oncology
  - 4.2.1.5. Nephrology
  - 4.2.1.6. Autoimmune Disease
  - 4.2.1.7. Dermatology
  - 4.2.1.8. Wound Care
  - 4.2.1.9. Others
4.3. Global Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals & Clinics
  - 4.3.1.2. Diagnostics Laboratories
  - 4.3.1.3. Academic and Research Institutes
  - 4.3.1.4. Biopharmaceutical Companies
4.4. Global Molecular Diagnostics Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. North America
  - 4.4.1.2. Europe
  - 4.4.1.3. Asia Pacific
  - 4.4.1.4. Latin America
  - 4.4.1.5. Middle East & Africa

5. North America Molecular Diagnostics Market Outlook, 2019 - 2031

5.1. North America Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Instruments
    - 5.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 5.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 5.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 5.1.1.1.4. Microarrays
  - 5.1.1.2. Reagent
    - 5.1.1.2.1. Antibodies
    - 5.1.1.2.2. DNA Template
    - 5.1.1.2.3. DNA Polymerase
    - 5.1.1.2.4. Oligonucleotide Primers
    - 5.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 5.1.1.2.6. Buffer
  - 5.1.1.3. Assay Kits
  - 5.1.1.4. Consumables
5.2. North America Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Infectious Disease
  - 5.2.1.2. Diabetes
  - 5.2.1.3. Cardiology
  - 5.2.1.4. Oncology
  - 5.2.1.5. Nephrology
  - 5.2.1.6. Autoimmune Disease
  - 5.2.1.7. Dermatology
  - 5.2.1.8. Wound Care
  - 5.2.1.9. Others
5.3. North America Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals & Clinics
  - 5.3.1.2. Diagnostics Laboratories
  - 5.3.1.3. Academic and Research Institutes
  - 5.3.1.4. Biopharmaceutical Companies
5.4. North America Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. U.S. Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 5.4.1.2. U.S. Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 5.4.1.3. U.S. Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 5.4.1.4. Canada Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 5.4.1.5. Canada Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 5.4.1.6. Canada Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Molecular Diagnostics Market Outlook, 2019 - 2031

6.1. Europe Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Instruments
    - 6.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 6.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 6.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 6.1.1.1.4. Microarrays
  - 6.1.1.2. Reagent
    - 6.1.1.2.1. Antibodies
    - 6.1.1.2.2. DNA Template
    - 6.1.1.2.3. DNA Polymerase
    - 6.1.1.2.4. Oligonucleotide Primers
    - 6.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 6.1.1.2.6. Buffer
  - 6.1.1.3. Assay Kits
  - 6.1.1.4. Consumables
6.2. Europe Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Infectious Disease
  - 6.2.1.2. Diabetes
  - 6.2.1.3. Cardiology
  - 6.2.1.4. Oncology
  - 6.2.1.5. Nephrology
  - 6.2.1.6. Autoimmune Disease
  - 6.2.1.7. Dermatology
  - 6.2.1.8. Wound Care
  - 6.2.1.9. Others
6.3. Europe Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals & Clinics
  - 6.3.1.2. Diagnostics Laboratories
  - 6.3.1.3. Academic and Research Institutes
  - 6.3.1.4. Biopharmaceutical Companies
6.4. Europe Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Germany Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.2. Germany Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.3. Germany Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.4. U.K. Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.5. U.K. Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.6. U.K. Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.7. France Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.8. France Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.9. France Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.10. Italy Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.11. Italy Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.12. Italy Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.13. Turkey Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.14. Turkey Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.15. Turkey Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.16. Russia Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.17. Russia Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.18. Russia Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.19. Rest of Europe Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.20. Rest of Europe Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 6.4.1.21. Rest of Europe Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Molecular Diagnostics Market Outlook, 2019 - 2031

7.1. Asia Pacific Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Instruments
    - 7.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 7.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 7.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 7.1.1.1.4. Microarrays
  - 7.1.1.2. Reagent
    - 7.1.1.2.1. Antibodies
    - 7.1.1.2.2. DNA Template
    - 7.1.1.2.3. DNA Polymerase
    - 7.1.1.2.4. Oligonucleotide Primers
    - 7.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 7.1.1.2.6. Buffer
  - 7.1.1.3. Assay Kits
  - 7.1.1.4. Consumables
7.2. Asia Pacific Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Infectious Disease
  - 7.2.1.2. Diabetes
  - 7.2.1.3. Cardiology
  - 7.2.1.4. Oncology
  - 7.2.1.5. Nephrology
  - 7.2.1.6. Autoimmune Disease
  - 7.2.1.7. Dermatology
  - 7.2.1.8. Wound Care
  - 7.2.1.9. Others
7.3. Asia Pacific Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals & Clinics
  - 7.3.1.2. Diagnostics Laboratories
  - 7.3.1.3. Academic and Research Institutes
  - 7.3.1.4. Biopharmaceutical Companies
7.4. Asia Pacific Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. China Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.2. China Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.3. China Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.4. Japan Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.5. Japan Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.6. Japan Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.7. South Korea Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.8. South Korea Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.9. South Korea Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.10. India Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.11. India Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.12. India Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.13. Southeast Asia Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.14. Southeast Asia Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.15. Southeast Asia Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.16. Rest of Asia Pacific Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.17. Rest of Asia Pacific Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 7.4.1.18. Rest of Asia Pacific Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Molecular Diagnostics Market Outlook, 2019 - 2031

8.1. Latin America Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Instruments
    - 8.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 8.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 8.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 8.1.1.1.4. Microarrays
  - 8.1.1.2. Reagent
    - 8.1.1.2.1. Antibodies
    - 8.1.1.2.2. DNA Template
    - 8.1.1.2.3. DNA Polymerase
    - 8.1.1.2.4. Oligonucleotide Primers
    - 8.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 8.1.1.2.6. Buffer
  - 8.1.1.3. Assay Kits
  - 8.1.1.4. Consumables
8.2. Latin America Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Infectious Disease
  - 8.2.1.2. Diabetes
  - 8.2.1.3. Cardiology
  - 8.2.1.4. Oncology
  - 8.2.1.5. Nephrology
  - 8.2.1.6. Autoimmune Disease
  - 8.2.1.7. Dermatology
  - 8.2.1.8. Wound Care
  - 8.2.1.9. Others
8.3. Latin America Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals & Clinics
  - 8.3.1.2. Diagnostics Laboratories
  - 8.3.1.3. Academic and Research Institutes
  - 8.3.1.4. Biopharmaceutical Companies
8.4. Latin America Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Brazil Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.2. Brazil Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.3. Brazil Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.4. Mexico Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.5. Mexico Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.6. Mexico Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.7. Argentina Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.8. Argentina Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.9. Argentina Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.10. Rest of Latin America Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.11. Rest of Latin America Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 8.4.1.12. Rest of Latin America Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Molecular Diagnostics Market Outlook, 2019 - 2031

9.1. Middle East & Africa Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 9.1.1. Key Highlights
  - 9.1.1.1. Instruments
    - 9.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
    - 9.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    - 9.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    - 9.1.1.1.4. Microarrays
  - 9.1.1.2. Reagent
    - 9.1.1.2.1. Antibodies
    - 9.1.1.2.2. DNA Template
    - 9.1.1.2.3. DNA Polymerase
    - 9.1.1.2.4. Oligonucleotide Primers
    - 9.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    - 9.1.1.2.6. Buffer
  - 9.1.1.3. Assay Kits
  - 9.1.1.4. Consumables
9.2. Middle East & Africa Molecular Diagnostics Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 9.2.1. Key Highlights
  - 9.2.1.1. Infectious Disease
  - 9.2.1.2. Diabetes
  - 9.2.1.3. Cardiology
  - 9.2.1.4. Oncology
  - 9.2.1.5. Nephrology
  - 9.2.1.6. Autoimmune Disease
  - 9.2.1.7. Dermatology
  - 9.2.1.8. Wound Care
  - 9.2.1.9. Others
9.3. Middle East & Africa Molecular Diagnostics Market Outlook, by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 9.3.1. Key Highlights
  - 9.3.1.1. Hospitals & Clinics
  - 9.3.1.2. Diagnostics Laboratories
  - 9.3.1.3. Academic and Research Institutes
  - 9.3.1.4. Biopharmaceutical Companies
9.4. Middle East & Africa Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 9.4.1. Key Highlights
  - 9.4.1.1. GCC Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.2. GCC Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.3. GCC Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.4. South Africa Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.5. South Africa Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.6. South Africa Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.7. Egypt Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.8. Egypt Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.9. Egypt Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.10. Nigeria Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.11. Nigeria Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.12. Nigeria Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.13. Rest of Middle East & Africa Molecular Diagnostics Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.14. Rest of Middle East & Africa Molecular Diagnostics Market by Disease Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
  - 9.4.1.15. Rest of Middle East & Africa Molecular Diagnostics Market by End Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2031
- 9.4.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

10.1. Product Type vs Material Heatmap
10.2. Manufacturer vs Material Heatmap
10.3. Company Market Share Analysis, 2023
10.4. Competitive Dashboard
10.5. Company Profiles
- 10.5.1. Becton, Dickinson and Company
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Product Portfolio
  - 10.5.1.3. Financial Overview
  - 10.5.1.4. Business Strategies and Development
- 10.5.2. Merck KgaA
  - 10.5.2.1. Company Overview
  - 10.5.2.2. Product Portfolio
  - 10.5.2.3. Financial Overview
  - 10.5.2.4. Business Strategies and Development
- 10.5.3. Thermo Fisher Scientific Inc
  - 10.5.3.1. Company Overview
  - 10.5.3.2. Product Portfolio
  - 10.5.3.3. Financial Overview
  - 10.5.3.4. Business Strategies and Development
- 10.5.4. Agilent Technologies, Inc.
  - 10.5.4.1. Company Overview
  - 10.5.4.2. Product Portfolio
  - 10.5.4.3. Financial Overview
  - 10.5.4.4. Business Strategies and Development
- 10.5.5. F. Hoffman - La Roche Ltd.
  - 10.5.5.1. Company Overview
  - 10.5.5.2. Product Portfolio
  - 10.5.5.3. Financial Overview
  - 10.5.5.4. Business Strategies and Development
- 10.5.6. Illumina, Inc.
  - 10.5.6.1. Company Overview
  - 10.5.6.2. Product Portfolio
  - 10.5.6.3. Financial Overview
  - 10.5.6.4. Business Strategies and Development
- 10.5.7. Qiagen N.V.
  - 10.5.7.1. Company Overview
  - 10.5.7.2. Product Portfolio
  - 10.5.7.3. Financial Overview
  - 10.5.7.4. Business Strategies and Development
- 10.5.8. Hologic Inc.
  - 10.5.8.1. Company Overview
  - 10.5.8.2. Product Portfolio
  - 10.5.8.3. Financial Overview
  - 10.5.8.4. Business Strategies and Development
- 10.5.9. Siemens Healthineers AG
  - 10.5.9.1. Company Overview
  - 10.5.9.2. Product Portfolio
  - 10.5.9.3. Financial Overview
  - 10.5.9.4. Business Strategies and Development
- 10.5.10. Seegene, Inc.
  - 10.5.10.1. Company Overview
  - 10.5.10.2. Product Portfolio
  - 10.5.10.3. Financial Overview
  - 10.5.10.4. Business Strategies and Development
- 10.5.11. DiaSorin S.p.A
  - 10.5.11.1. Company Overview
  - 10.5.11.2. Product Portfolio
  - 10.5.11.3. Financial Overview
  - 10.5.11.4. Business Strategies and Development
- 10.5.12. Grifols, S.A.
  - 10.5.12.1. Company Overview
  - 10.5.12.2. Product Portfolio
  - 10.5.12.3. Financial Overview
  - 10.5.12.4. Business Strategies and Development
- 10.5.13. bioMerieux
  - 10.5.13.1. Company Overview
  - 10.5.13.2. Product Portfolio
  - 10.5.13.3. Financial Overview
  - 10.5.13.4. Business Strategies and Development
- 10.5.14. QuidelOrtho Corporation
  - 10.5.14.1. Company Overview
  - 10.5.14.2. Product Portfolio
  - 10.5.14.3. Financial Overview
  - 10.5.14.4. Business Strategies and Development
- 10.5.15. RapidBio
  - 10.5.15.1. Company Overview
  - 10.5.15.2. Product Portfolio
  - 10.5.15.3. Financial Overview
  - 10.5.15.4. Business Strategies and Development
- 10.5.16. Abbott Laboratories
  - 10.5.16.1. Company Overview
  - 10.5.16.2. Product Portfolio
  - 10.5.16.3. Financial Overview
  - 10.5.16.4. Business Strategies and Development
- 10.5.17. Danaher Corporation
  - 10.5.17.1. Company Overview
  - 10.5.17.2. Product Portfolio
  - 10.5.17.3. Financial Overview
  - 10.5.17.4. Business Strategies and Development

11. Appendix

11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations